Amylyx Pharmaceuticals, Inc. Common Stock Revenue 2021–2025
Amylyx Pharmaceuticals, Inc. Common Stock annual/quarterly revenue history and growth rate from 2021 to 2025. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Amylyx Pharmaceuticals, Inc. Common Stock revenue for the quarter ending September 30, 2025 was 0, a 100.00% decrease year-over-year.
- Amylyx Pharmaceuticals, Inc. Common Stock revenue for the twelve months ending September 30, 2025 was 416000, a 99.86% decrease year-over-year.
- Amylyx Pharmaceuticals, Inc. Common Stock annual revenue for 2025 was 0, a 100.00% decrease from 2024.
- Amylyx Pharmaceuticals, Inc. Common Stock annual revenue for 2024 was 87.4 M, a 77.06% decrease from 2023.
- Amylyx Pharmaceuticals, Inc. Common Stock annual revenue for 2023 was 380.8 M, a 1612.94% increase from 2022.
- Amylyx Pharmaceuticals, Inc. Common Stock annual revenue for 2022 was 22.2 M.
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) — Frequently Asked Questions
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) is a publicly traded US company. It has a market capitalization of $1.27B. Explore AMLX's stock price, financial statements, earnings history, margins and key ratios below.
What is Amylyx Pharmaceuticals, Inc. Common Stock's market cap?
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) has a market capitalization of $1.27B.
What is the AMLX stock price?
AMLX trades at $13.46 (-0.66% on the day).
Is AMLX profitable?
In fiscal 2025, Amylyx Pharmaceuticals, Inc. Common Stock reported net income of -$145M.